Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.

Armstrong, April W; Soliman, Ahmed M; Betts, Keith A; Wang, Yan; Gao, Yawen; Stakias, Vassilis; Puig, Luis

Armstrong, April W; Soliman, Ahmed M; Betts, Keith A; Wang, Yan; Gao, Yawen; Stakias, Vassilis; Puig, Luis.

Afiliação

Armstrong AW; Department of Dermatology, Keck School of Medicine, University of Southern California, HC4 2000 1450 San Pablo, Health Sciences Campus, Los Angeles, CA, 90033, USA. aprilarmstrong@post.harvard.edu.
Soliman AM; AbbVie, Inc., 1 N. Waukegan Road, North Chicago, IL, 60064, USA.
Betts KA; Analysis Group, Inc., 333 South Hope Street 27th Floor, Los Angeles, CA, 90071, USA.
Wang Y; Analysis Group, Inc., 333 South Hope Street 27th Floor, Los Angeles, CA, 90071, USA.
Gao Y; Analysis Group, Inc., 333 South Hope Street 27th Floor, Los Angeles, CA, 90071, USA.
Stakias V; AbbVie, Inc., 26525 N. Riverwoods Blvd, Mettawa, IL, 60045, USA.
Puig L; Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Carrer de Sant Quintí, 89, 08041, Barcelona, Spain.

Dermatol Ther (Heidelb) ; 12(1): 167-184, 2022 Jan.

Article em En | MEDLINE | ID: mdl-34862951

Palavras-chave

Bimekizumab; Ixekizumab; Long-term benefitrisk profile; Moderate-to-severe plaque psoriasis; Network meta-analysis; Risankizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google